CORTICOSTEROID THERAPY FOR PATIENTS HOSPITALIZED WITH COMMUNITY-ACQUIRED PNEUMONIA: A SYSTEMATIC REVIEW
DOI:
https://doi.org/10.53555/nnmhs.v9i8.1809Keywords:
Community-acquired pneumonia, Corticosteroid, InflammationAbstract
Introduction: Pneumonia is an inflammation of the lung parenchyma in the distal terminal bronchioles, which includes the respiratory bronchioles and alveoli. Corticosteroids are routinely used for severe pneumonia symptoms. Numerous studies on adjuvant corticosteroids for community-acquired pneumonia (CAP) have yielded equivocal results. Several systematic reviews and meta-analyses have studied the efficacy of corticosteroids in treating CAP.
The aim: This article showed about corticosteroid therapy for patients hospitalized with community-acquired pneumonia (CAP).
Methods: By comparing itself to the standards set by the Preferred Reporting Items for Systematic Review and MetaAnalysis (PRISMA) 2020, this study was able to show that it met all of the requirements. So, the experts were able to make sure that the study was as up-to-date as it was possible to be. For this search approach, publications that came out between 2013 and 2023 were taken into account. Several different online reference sources, like Pubmed and SagePub, were used to do this. It was decided not to take into account review pieces, works that had already been published, or works that were only half done.
Result: The PubMed database yielded a total of 423 articles in response to our search query, while the search conducted on SagePub retrieved 491 articles. The search run for the last year of 2013 generated a total of 223 articles from PubMed and 212 articles from SagePub. Ultimately, a cumulative sum of 21 scholarly articles was assembled, with 15 originating from the PubMed database and the other six sourced from SagePub. We have incorporated four studies that satisfied the specified criteria.
Conclusion: Administration of steroids as early as possible in patients with severe CAP who are treated to benefit, where they do not experience therapy failure. Slower administration and inadequate doses do not provide any benefit.
References
Aliberti S, Dela Cruz CS, Amati F, Sotgiu G, Restrepo MI. Community-acquired pneumonia. Lancet (London, England). 2021 Sep;398(10303):906–19.
Fishman JA, Grippi MA, Kotloff RM, et al. Fishman’s Pulmonary Disease and Disorders Fifth Edition. New York: Elsevier Saunder; 2016.
Stamm DR; Stankewicz HA. Atypical Bacterial Pneumonia [Internet] StarPearls; 2020. Available from: https://www.ncbi.nlm.nih.gov/books/NBK532239/#_NBK532239_pubdet_
Jain S, Williams DJ, Arnold SR, Ampofo K, Bramley AM, Reed C, et al. Community-acquired pneumonia requiring hospitalization among U.S. children. N Engl J Med. 2015 Feb;372(9):835–45.
Ramirez JA; Wiemken TL; Peyrani P; et al. Adults Hospitalized With Pneumonia in the United States: Incidence, Epidemiology, and Mortality. Clin Infect Dis. 2017;65(11):1806–12.
Gramegna A; Sotgiu G; Pasquale MD; et al. Atypical pathogens in hospitalized patients with community-acquired pneumonia: a worldwide perspective. BMC Infect Dis. 2018;18:677.
Thakuria B, Singh P, Agrawal S, et al. Profile of infective microorganisms causing ventilator-associated pneumonia:
A clinical study from resource limited intensive care unit. J Anaesthesiol Clin Pharmacol. 2013;29(3):361–6.
Torres A, Chalmers JD, Dela Cruz CS, Dominedò C, Kollef M, Martin-Loeches I, et al. Challenges in severe community-acquired pneumonia: a point-of-view review. Intensive Care Med. 2019 Feb;45(2):159–71.
Martin-Loeches I, Torres A. New guidelines for severe community-acquired pneumonia. Curr Opin Pulm Med. 2021 May;27(3):210–5.
Huang J, Guo J, Li H, Huang W, Zhang T. Efficacy and safety of adjunctive corticosteroids therapy for patients with severe community-acquired pneumonia: A systematic review and meta-analysis. Medicine (Baltimore). 2019 Mar;98(13):e14636.
Stern A, Skalsky K, Avni T, Carrara E, Leibovici L, Paul M. Corticosteroids for pneumonia. Cochrane database Syst Rev. 2017 Dec;12(12):CD007720.
Dequin P-F, Meziani F, Quenot J-P, Kamel T, Ricard J-D, Badie J, et al. Hydrocortisone in Severe CommunityAcquired Pneumonia. N Engl J Med. 2023 May;388(21):1931–41.
Meduri GU, Shih M-C, Bridges L, Martin TJ, El-Solh A, Seam N, et al. Low-dose methylprednisolone treatment in critically ill patients with severe community-acquired pneumonia. Intensive Care Med. 2022 Aug;48(8):1009–23.
Odeyemi YE, Herasevich S, Chalmers SJ, Barreto EF, Frank RD, Gajic OO, et al. Biomarker-Concordant Steroid Use in Critically Ill Patients with Pneumonia. Mayo Clin proceedings Innov Qual outcomes. 2020 Dec;4(6):649–56.
Torres A, Sibila O, Ferrer M, Polverino E, Menendez R, Mensa J, et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA. 2015 Feb;313(7):677–86.
Benedek TG. History of the development of corticosteroid therapy. Clin Exp Rheumatol. 2011;29(5 Suppl 68):5– 12.
Guyton A, Hall J. Buku Ajar Fisiologi Kedokteran. Jakarta: EGC; 2016.
Ando H, Ukena K, Nagata S. Handbook of hormones: comparative endocrinology for basic and clinical research. Academic Press; 2021.
Gardner DG, Shoback DM. Greenspan’s basic and clinical endocrinology. McGraw-Hill Education; 2017.
Bruntol L, Dandan R, Knollmann B. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics. Philadelphia: Mc Graw Hill Education; 2018.
Nicolaides NC; Galata Z; Kino T; et al. The human glucocorticoid receptor: molecular basis of biologic function. Steroids. 2010;75(1):1–12.
Nicolaides NC, Pavlaki AN, Alexandra MAM, et al. Glucocorticoid Therapy and Adrenal Suppression. Endotext. 2018.
Gupta P; Bhatia V. Corticosteroid Physiology and Principles of Therapy. Indian J Pediatr. 2008;76:1039–44.
Li J, Liao X, Zhou Y, Wang L, Yang H, Zhang W, et al. Comparison of Associations Between Glucocorticoids Treatment and Mortality in COVID-19 Patients and SARS Patients: A Systematic Review and Meta-Analysis. Shock. 2021 Aug;56(2):215–28.
Meduri GU, Annane D, Confalonieri M, Chrousos GP, Rochwerg B, Busby A, et al. Pharmacological principles guiding prolonged glucocorticoid treatment in ARDS. Intensive Care Med. 2020 Dec;46(12):2284–96.
Prina E, Ceccato A, Torres A. New aspects in the management of pneumonia. Crit Care. 2016 Oct;20(1):267.
Pandya D, Puttanna A, Balagopal V. Systemic effects of inhaled corticosteroids: an overview. Open Respir Med J. 2014;8:59.
Williams DM. Clinical Pharmacology of Corticosteroids. Respir Care [Internet] 2018 Jun 1;63(6):655 LP – 670. Available from: http://rc.rcjournal.com/content/63/6/655.abstract
Dropulic LK, Lederman HM. Overview of Infections in the Immunocompromised Host. Microbiol Spectr. 2016;4(4):10–28.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
